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Background. Myeloid sarcoma is well described and known in clinical practice, however,
it is a rare condition after receiving renal transplantation. Immunosuppressive therapy is
thought to be the main cause in these cases.
Case Report. A 45-year-old woman accepted a right kidney transplantation because of her
chronic renal insufﬁciency and uremia in May 2011. She had to receive a left kidney
transplantation again in February 2012 because she had renal failure again after receiving
the right kidney transplantation. She received immune inhibitors treatment. After the
latter operation, her renal function was normal. The third operation was done to remove
the right transplanted kidney in July 2012. The diagnosis of the kidney was myeloid
sarcoma. The blood and bone marrow biopsy had no evidence of leukemia. She then
received chemotherapy. There was a small skin nodule on the left arm of approximately
0.5 cm in August 2012; after that its diameter enlarged progressively to about 5 cm and
more nodules and masses gradually appeared on her face, arms, trunk, lower limbs, and
feet over the course of 1 year. The skin biopsy specimen obtained from her left arm
showed myeloid sarcoma too. She was admitted to the Orthopedics Department for
severe pain and swelling in the left foot in September 2014 and underwent an operation
for resecting the mass in the left foot. Pain was apparently alleviated and the incision
healed well.
Conclusions. Thepatient is still alivewithnoevidenceof leukemiaaftera30-month follow-up.*Address correspondence to Xinru Du, MD, Department of
Orthopedics, Beijing Chaoyang Hospital, Capital Medical Uni-
versity, NO.8, Baijiazhuang Road, Chaoyang District, Beijing,
China. E-mail: duxinru@163.comMYELOID SARCOMA (MS) is a rare, extramedullarymalignant tumor composed of leukemic myeloblasts
or immature myeloid cells. It is often misdiagnosed in clinical
practice as some other disease. To our knowledge, there are
few articles about MS after 2-time kidney transplantations
although many authors have discussed MS in other organs.
Herein we present an atypical case with multiple skin and
subcutaneous lesions after renal transplantation. The result
of bone marrow aspiration was normal without any evidence
of leukemia. Up to now, the etiology ofMSwith multiple skin
and subcutaneous masses is unknown.
CASE REPORT
A 45-year-old woman was admitted to our department in
September 2014 with a more than 2-year history of multiple skinAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
enue South, New York, NY 10010-1710
ion Proceedings, 47, 2227e2232 (2015)and subcutaneous mass complaining of obvious pain and swelling
on the dorsal region of her left foot. The patient had a 2-time
allogenic renal transplantation medical history. The donor was
healthy without any medical history. She accepted a surgical right
kidney transplantation because of chronic renal insufﬁciency and
uremia in the Department of Urology of our hospital in May 2011.
In February 2012, she received a left kidney transplantation again in
the same department as the previous transplanted kidney because
of renal dsyfunction. She received immune inhibitors treatment
including neoral, mycophenolate mofetil, and prednisone. After
this, the function of the latter transplanted kidney was normal.0041-1345/15
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Fig 1. In August 2012, it was ﬁrst found that there was a small
skin nodule presenting on the left arm with a diameter of approxi-
mately 0.5 cm, with smooth surface, no activity, and no tenderness;
after that its diameter enlarged progressively to more about 3.0 cm;
after 1 year, more and more nodules and masses gradually
appeared on her face, right arm, trunk, chest wall, abdominal
wall, lower limbs, and feet except the right leg with skin grafting
because of skin avulsion in a trafﬁc accident.
2228 SHEN, DU, DIAO ET ALSerum creatinine level ranged from 60 to 80 mmol/L. Color doppler
ultrasound of the right transplanted kidney showed that the
enlarged size was measured 14.3 10.8 cm with disordered inner
structure, poor blood supply, and enhanced echogenic renal pa-
renchyma in June 2012. Then she underwent the third operation to
remove the right previously transplanted kidney in July 2012. The
histopathological diagnosis of the resected kidney was MS. The
blood and bone marrow biopsy showed no evidence of leukemia. In
August 2012, it was ﬁrst found that there was a small skin nodule
presenting on the left arm with a diameter of approximately 0.5 cm,
with smooth surface, no activity, and no tenderness; after that its
diameter enlarged progressively to more about 3.0 cm; after 1 year,
more and more nodules and masses gradually appeared on her face,
right arm, trunk, chest wall, abdominal wall, lower limbs, and feet
except the right leg with skin grafting because of skin avulsion in a
trafﬁc accident (Figs 1 and 2). The total number of those masses
was almost 500. The skin biopsy specimen obtained from her left
arm demonstrated the same result as MS. On physical examination,there were multiple scattered dark red and brown skin masses of
various sizes (range, 1 cme3 cm) and subcutaneous masses mainly
located on the bilateral proximal upper extremity, the back, and the
bottom of the left foot with various diameters (range, 2 cme6 cm).
The whole-body masses were with no tenderness, no activity, hard
feeling, and did not fade with pressure. The blood cell count showed
the following: white blood cell (3.09  109/L), neutrophile gran-
ulocyte (77.7%), red blood cell (3.01  1012/L), and hemoglobin
(83 g/L). Flow cytometry of the peripheral blood was completely
normal, without evidence of leukemia. Pathological result of the
biopsy was that it was composed of a relatively uniform population
of immature small round cells. Immunohistochemistry revealed
LCA(-), MPO(þ), S-100(3þ), CD68(þ), CD1a(-), CD163(-),
TdT(-), CK(-), CD3(-), CD5(-), CD20(-), CD34(-), and Ki-67
(60%þ; Figs 3 and 4). These ﬁndings were consistent with a diag-
nosis of MS. Then bone marrow aspiration was performed. The
bone marrow smears showed normal results, with no parasite and
no other disease. Combination systematic chemotherapy was star-
ted with daunorubicin 40 mg days 1e3 and cytarabine 200 mg days
1e5 (regimen DA) subsequently. The patient has shown a very good
response to the treatment, and the size of the subcutaneous mass
decreased. The chemotherapy regimen DA was given to the patient
again 26 days later for 1 cycle. After 9 days, the patient was treated
with cytarabine 2 g/d for 3 consecutive days. Then the second
bone marrow aspiration was done in October 2012. The result
revealed bone marrow hyperplasia and primitive granulocyte
occupied 0.5%. The patient was then given medium-dose cytar-
abine (2 g days 1e3) for 2 cycles. After that, she received 2 cycles
of MAE regimen with a dose of mitoxantrone (6 mg) for 3
consecutive days, cytarabine (200 mg) for 7 consecutive days, and
etoposide (100 mg) for intermittent 3 days. Then the patient
appeared to have fourth-degree bone marrow suppression and
severe acute respiratory system infection. After this therapy, she
received symptomatic and supportive treatment including anti-
infection, blood and platelet transfusion and then she recov-
ered. In August 2013, she found a mass that presented in her right
breast. The mammogram conﬁrmed the presence of a 2.7  3.2 
2.3 cm mass with unclear and burr boundary in the upper outer
quadrant of her right breast, which consisted of high-density soft
tissue (Fig 5). Malignant breast tumor was ﬁrst considered. The
biopsy and immunohistochemistry of the mass in her right breast
revealed MS. She underwent radiotherapy treatment, and the
mass reduced and then and disappeared. Subsequently, she
accepted regular systematic chemotherapy and no bone marrow
recurrence was found.
In July 2014, the subcutaneous mass in the left foot caused pain
and swelling. The ultrasound examination of her left foot showed
that the mass with an unclear boundary was rich in blood supply.
Several dorsal extensor tendons and the dorsal artery of the left foot
were wrapped by the mass. She underwent an operation for resecting
the lesion in the left foot. We took an “S” shape incision, and found
that the border of the tumor was not clear; the dorsalis pedis artery
and vein, cutaneous nerve, and dorsal extensor tendons were wrap-
ped in the tumor (Fig 6). Foot dorsal bone joint capsule and ligament
were also involved.We tried our best to resect the tumor and protect
the dorsal artery of the foot, extensor pollicis longus muscle tendon,
and extensor longus digitorum. After the operation, the patient’s
symptoms were alleviated obviously and the incision healed well.
Visual analogue scale (VAS) score decreased from 8 to 3. The
appearance of the resected tumor had a ﬁsh-like, delicate texture and
its color was gray or blackish green on the cross section (Fig 7).
Fig 2. In August 2012, it was ﬁrst found
that there was a small skin nodule pre-
senting on the left arm with a diameter
of approximately 0.5 cm, with smooth
surface, no activity, and no tenderness;
after that its diameter enlarged progres-
sively to more about 3.0 cm; after 1
year, more and more nodules and
masses gradually appeared on her right
arm, trunk, and back.
MYELOID SARCOMA AFTER RENAL TRANSPLANTATION 2229Immunohistochemistry examination revealed MS which was in
accordance with the pathological result of the subcutaneous mass
and the resected kidney. There was no signiﬁcant past, personal, and
family history except the right leg with a skin graft because of skin
avulsion in a trafﬁc accident, and there was no history of loss of
weight. There were no other positive ﬁndings on systemic examina-
tion. Blood investigations revealed mild anemia with leukocytes
count 8.54  109/L, red blood cell count 2.34  1012/L, platelets
count 68  109/L, total proteins 65.9 g/L, globulin 34.8 g/L, and
hemoglobin 72.0 g/L. Albumin was 31.1 g/L. Creatinine was at the
normal level (88.40 mmol/L). The last follow-up time was January
2015. She had no evidence of leukemia during the 30-month
follow-up and her bone marrow biopsy showed excellent result.
The function of the left transplanted kidney was normal up to now.
The patient is alive and satisﬁed.Fig 3. Immunohistochemistry revealed LCA(-), MPO(þ),
S-100(3þ), CD68(þ), CD1a(-), CD163(-), TdT(-), CK(-), CD3(-),
CD5(-), CD20(-), CD34(-).DISCUSSION
MS was ﬁrst described in 1811 by Bunrs and was originally
called “chloroma” by King in 1853, involving 1 or more
anatomical sites. MS is a rare, extramedullary tumor composed
of leukemic myeloblasts or immature myeloid cells [1].The
synonyms of this pathological entity include granulocytic
sarcoma, chloroma, myeloblastoma, chloromyeloma, chlor-
omyelosarcoma, granulocytic leukosarcoma, or myelosarcoma
[2]. In the 2002 World Health Organization classiﬁcation of
myeloid neoplasms, the terms “granulocytic sarcoma” and
“chloroma” that were commonly used to refer to such tumors
were replaced with “myeloid sarcoma” [3]. MS may appear at
any age and involves almost all tissues, but the most common
sites include skin, soft tissue, periosteum, lymph nodes, spine,
orbit, the central nervous system, and bone [4,5]. MS occurs
both in males and in females, and there is no signiﬁcant dif-
ference in gender. MS is generally observed as a complication
of acutemyeloid leukemia (AML),myelodysplastic syndromes,
or myeloproliferative disorders, and it may be perceived as a denovo tumor without marrow involvement or as a tumor asso-
ciated with leukemia in the marrow, and as a site of leukemia
relapse [6]. MS may also precede the onset of systemic disease.
MS has been associated with 3.1%e9.1% of AML cases and
been the ﬁrst clinical manifestation in 0.6%e2.9% of AML
cases. Recent evidence suggests that the incidence of MS
increased signiﬁcantly, which was closely related to the
improvement of antileukemic treatment method. However,
MS can be also encountered in patients with no history of he-
matologic disorder like the patient in our case who has not been
diagnosed as having leukemia up to now. Although MS can
occur anywhere in the body, so large a quantity of skin and
subcutaneous mass is unusual, and, what is more, our case was
characterized by the typical clinical manifestation and following
renal transplantation. The masses appeared on almost her
Fig 4. Immunohistochemistry revealed LCA(-), S-100(3þ),
CD68(þ), CD1a(-), CD163(-), TdT(-), CK(-), CD3(-), CD5(-),
CD20(-), CD34(-), and Ki-67 (60%þ).
2230 SHEN, DU, DIAO ET ALwhole body except her right leg, which had suffered skin
grafting. To our knowledge, it was the ﬁrst case related to renal
transplantation and skin grafting, but the reason for this is still
unknown.Fig 5. The mammogram conﬁrmed the presence of a 2.7 
3.2  2.3 cm mass with unclear and burr boundary in the upper
outer quadrant of her right breast, which consisted of high-
density soft tissue.
Fig 6. We took an “S” shape incision, and found that the border of
the tumorwasnot clear; thedorsalis pedis artery andvein, cutaneous
nerve, and dorsal extensor tendons were wrapped in the tumor.In general, MS was classiﬁed into 3 types: (1) granulocytic
sarcoma; (2) monoblastic sarcoma; and (3) sarcoma composed
of trilineage hematopoietic cells. The most common type of
MS is the granulocytic sarcoma composed of myeloblasts and
neutrophils. The less common type, monoblastic sarcoma, has
similar surface antigens to that of monoblasts in acute
monoblastic leukemias. In our case, the pathological exami-
nation and immunophenotypic detection revealed granulo-
cytic sarcoma. MS was also classiﬁed into isolated MS and
leukemic MS depending on whether it was accompanied by
leukemia. Isolated MS can also be named nonleukemic MS
when the bone marrow biopsy shows normal results within 30
days after the diagnosis of MS. Compared with the isolated
MS, leukemic MS is diagnosed easier with poorer prognosis
and shorter survival time. Leukemic MS occurs in 2%e8% of
AML cases and 4.0%e4.5% of CML cases. In our case, it was
conﬁrmed as isolated MS because of no evidence of leukemia
disease during the whole course, despite so such more skin
and subcutaneous mass.
Fig 7. The appearance of the resected tumor had a ﬁsh-like,
delicate texture and its color was gray or blackish green on the
cross section.
MYELOID SARCOMA AFTER RENAL TRANSPLANTATION 2231Immunohistochemical study played an important role in
arriving at a correct diagnosis of MS. The diagnosis is often
difﬁcult when the myeloblastic cells are poorly differentiated
and the symptoms are secondary to the mass effect of the
tumor, and the patient may be initially misdiagnosed with non-
Hodgkin’s lymphoma, a small round cell tumor, or blastic
plasmacytoid dendritic cell neoplasm. The correct and prompt
diagnosis of MS was important for adequate therapy, which
was often delayed because of a high misdiagnosis rate [7].
Immunohistochemical staining including lysozyme, CD43,
CD45, MPO, CD117, CD68, CD3, and CD20 can successfully
identify the majority of cases of MS in formalin-ﬁxed, parafﬁn-
embedded tissue specimens. CD43 and lysozyme are the most
sensitive markers staining a large proportion of neoplastic cells
in all tumors examined. MPO and CD117 are the most sen-
sitive of the markers for myeloid differentiation, whereas
monocytic precursors consistently strongly expressed CD68
and CD163. The differential diagnosis includes Ewing sar-
coma, B-cell or T-cell lymphoma, Langerhans histiocytosis,
and metastatic tumors [8]. This case was diagnosed as gran-
ulocytic sarcoma according to immunohistochemical staining.
Therapies typically include local radiation, systemic chemo-
therapy, immunotherapy, surgery, hematopoietic stem cell
transplantation, donor lymphocyte infusion, and combination
therapy. MS is frequently a herald for AML. It was reported
that 71%of the patients diagnosedwithMSwho did not receive
antileukemic chemotherapy subsequently developed AML
within amedian time of 7months. Also, in Tsimberidou’s study,
anti-AML therapy is highly effective in patients with non-
leukemic MS and is associated with higher rates of disease-free
survival in MS than in AML after comparing MS patients with
typical AML patients [9]. Radiation has a better response in
nonleukemic patients with local lesion, and single radiation
treatment cannot hinder the progress of leukemia. This casewas MS with nonleukemia; the patient accepted combination
therapy including local radiation, systemic chemotherapy,
immunotherapy, and surgery. Her survival period reached
more than 30months. Compared with other reports, it is one of
the longest cases up to now.
MS is a rare situation observed in patients after kidney
transplantation. AlGhunaim et al reported the ﬁrst case of
acute MS after renal transplantation [10] in which only
intrarenal and perirenal masses were found, not including
multiple skin and subcutaneous mass, which is mostly
different from our case. Intensive immunosuppression
caused by immune inhibitors has a large effect on the type
of cancer and the incidence [11]. Intensive immunosup-
pression could cause damage to the normal DNA, which
may lead to cancer. Another risk factor for developing
cancer after transplantation is history of pretransplantation
neoplasm. In our case, the patient herself and the donor had
no history of cancer. Harzallah et al [12] reported that
incidence of cancer among their population was 7% and
occurred after a mean period of 54 months of trans-
plantation (range, 4e160 months). The period between the
ﬁrst renal transplantation and the appearence of MS in our
case was 15 months, which conforms to the reported data.
The tumors reported in Harzallah et al’s study are skin
cancer including spinocellular carcinoma (SCC), basocel-
lular carcinoma (BCC), and Bowen’s disease and solid
cancers including post-transplantation lymphoproliferative
disease (PTLD), melanoma, Kaposi’s sarcoma, and Merkel
cell carcinoma, in which MS is not included. To our
knowledge, this is the ﬁrst MS case presenting with so large
a quantity of skin and subcutaneous mass without leukemic
manifestations after undergoing renal transplantation.
Because the diagnosis of MS in the resected kidney was
prior to multiple skin and subcutaneous mass, ﬁrst, we could
not rule out the possibility that the multiple skin and sub-
cutaneous mass is the recurrence of MS from the trans-
planted kidney. Second, we can also suppose that it is a
consecutive process. MS was located in the kidney initially,
and, then, the tumor cells were transported to the whole-
body skin and subcutaneous tissue by blood metastasis
from the involved kidney.
In conclusion, a large quantity of skin and subcutaneous
masses after undergoing renal transplantation is a rare sit-
uation. Surgical excision achieved local control and the
quality of the patient’s daily life was improved. VAS score
decreased from 8 to 3. Further studies should clarify the
clinical characteristics and exact pathogenic mechanism.REFERENCES
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